Results 11 to 20 of about 126,024 (329)

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis

Journal of Experimental & Clinical Cancer Research, 2023
Background Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore
Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo   +13 more
doaj   +2 more sources

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase

Cell Death and Disease, 2023
Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), shows a favorable anti-tumor effect while resistance is a barrier impeding patients from benefiting from it. Thus, more efforts are needed to lift this restriction.
Feng-li Xu, Xiao-hong Wu, Chang Chen, Kai Wang, Lu-yi Huang, Jie Xia, Yi Liu, Xue-feng Shan, Ni Tang   +8 more
doaj   +2 more sources

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

JAMA Oncology, 2023
Key Points Question How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings In this phase 3 randomized clinical trial of 674
Shukui Qin, M. Kudo, Tim Meyer, Y. Bai, Yabing Guo, Zhiqiang Meng, T. Satoh, D. Marino, E. Assenat, Songzi Li, Yaxi Chen, F. Boisserie, Ramil Abdrashitov, R. Finn, Arndt Vogel, Andrew X. Zhu   +15 more
semanticscholar   +1 more source

YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis

EMBO Molecular Medicine, 2021
Understanding the mechanisms underlying evasive resistance in cancer is an unmet medical need to improve the efficacy of current therapies. In this study, a combination of shRNA‐mediated synthetic lethality screening and transcriptomic analysis revealed ...
Ruize Gao, R. Kalathur, M. Coto-Llerena, Caner Ercan, David Buechel, Song Shuang, S. Piscuoglio, Michael T. Dill, F. Camargo, G. Christofori, Fengyuan Tang   +10 more
semanticscholar   +1 more source

Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib

Cancer Communications, 2023
Cancer‐associated fibroblasts (CAFs) play an important role in the induction of chemo‐resistance. This study aimed to clarify the mechanism underlying CAF‐mediated resistance to two tyrosine kinase inhibitors (TKIs), sorafenib and lenvatinib, and to ...
J. Eun, Jung Hwan Yoon, H. Ahn, Seokhwi Kim, Young Bae Kim, S. Lim, Won Park, Tae Wook Kang, G. Baek, M. Yoon, J. Son, Ji Hyang Weon, Soon Sun Kim, H. Cho, J. Cheong   +14 more
semanticscholar   +1 more source

Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

Scientific Reports, 2021
Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy.
Shou-Sheng Chu, Yu-Hsuan Kuo, Wen-Shan Liu, Shih-Chang Wang, Chung-Han Ho, Yi-Chen Chen, Ching-Chieh Yang, Hung-Chang Wu   +7 more
doaj   +1 more source

Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway

Molecular and Cellular Probes, 2023
Backgrounds: Sorafenib-resistance leads to poor prognosis and high mortality in advanced hepatocellular carcinoma (HCC), and this study aims to investigate the functional role of a circular RNA ITCH (circITCH) in regulating the sorafenib-resistance of ...
Xiaodong Li, Xuedong Yin, Heyi Bao, Chang Liu   +3 more
doaj   +1 more source

Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF‐1α/SLC7A11 pathway

Cell Proliferation, 2021
Evidences demonstrate that sorafenib alleviates liver fibrosis via inhibiting HSC activation and ECM accumulation. The underlying mechanism remains unclear.
Siyu Yuan, Can Wei, Guo-juan Liu, Lijun Zhang, Jiahao Li, Lingling Li, Shiyi Cai, L. Fang   +7 more
semanticscholar   +1 more source

Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation

Clinical and Translational Medicine, 2023
Background Ferroptosis is an important iron‐dependent form of cell death in hepatocellular carcinoma (HCC). Sorafenib, a potent ferroptosis inducer, is used to treat advanced HCC but its efficacy is limited by the development of drug resistance.
Zhehao Shi, Zhiming Li, Bin Jin, W. Ye, Luhui Wang, Sina Zhang, Jiuyi Zheng, Zixia Lin, Bo Chen, Fangting Liu, Baofu Zhang, X. Ding, Zhen Yang, Y. Shan, Zhengping Yu, Yi Wang, Ji-Cai Chen, Qiang Chen, L. Roberts, Gang Chen   +19 more
semanticscholar   +1 more source

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [PDF]

, 2018
Background: This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs.
Deptala, A, Fartoux, L, Graham, J, Hocke, J, Loembé, A-B, Ma, Y T, Meyer, T, Palmer, D H, Peck-Radosavljevic, M, Ross, P, Schnell, D, Studeny, M   +11 more
core   +3 more sources